Shire Human Genetic Therapies, Inc. is a global leader in the bio-pharmaceutical industry with an emphasis on "enabling people with life-altering conditions to lead better lives." Headquartered in the United Kingdom, Shire operates in over 25 countries and employs approximately 4000 people through its two main business units, Specialty Pharmaceutical & Human Genetic Therapies. In 2008, the company announced an eight-year plan, comprised of a capital investment of $460 million and the creation of 750 jobs, to relocate its Human Genetic Therapies Division from Cambridge to Lexington. As the anchor tenant at Lexington Technology Park, Shire currently occupies approximately 460,000 square feet of space in four buildings. In August 2009, Shire signed a 15-year lease for a 160,000-square-foot facility that will hold offices and lab space. Shire's new building is scheduled for completion in 2010.

Concord Biomedical Sciences & Emerging Technologies (CBSET) is a not for profit company focused on research, education, and advancement of early stage technologies. They specialize in the development and application of novel, minimally invasive techniques across many sectors of health care. CBSET's goal is to assist clients in their endeavor to develop unique tools & methodologies for diagnosing and treating complex diseases.